| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
IN1341 targets mitochondria, specifically the mitochondrial membrane. As a delocalized lipophilic cation, it preferentially accumulates in mitochondria due to the negative membrane potential across the inner mitochondrial membrane. By binding to and disrupting mitochondrial membrane function, it acts as a mitochondrial toxin, leading to energy depletion and cell death. This mechanism contributes to its selective inhibition of proliferation of mammary epithelial and breast cancer cells.
|
|---|---|
| ln Vitro |
F16 (3 μM; 3 days/7 days) inhibits the development of several cancer cell lines in humans and mice [1]. F16-sensitive EpH4-A6 cells have increased apoptosis and cell cycle blockage [1].
IN1341 is a fluorescent and selective inhibitor of proliferation of mammary epithelial and neu-overexpressing cells. It also acts on a variety of mouse mammary tumor and human breast cancer cell lines. As a mitochondrial toxin, it preferentially binds to and disrupts mitochondrial membrane function. Its activity has been confirmed in various in vitro studies. |
| ln Vivo |
IN1341 selectively inhibits proliferation of mammary epithelial, neu-overexpressing cells, as well as a variety of mouse mammary tumor and human breast cancer cell lines. Its mitochondrial targeting mechanism makes it a potential candidate for cancer therapy. It has been studied for its effects on breast cancer cells.
|
| Enzyme Assay |
IN1341 does not have a typical enzyme/receptor binding assay. Its activity is assessed in cell-based proliferation assays using various cell lines, including mammary epithelial cells, neu-overexpressing cells, and breast cancer cell lines. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. Its mitochondrial targeting can be assessed by measuring mitochondrial membrane potential using fluorescent dyes.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: MDA-MB231, MDA-MB435, MDA-MB436, MDA-MB453, MDA-MB-468, SKBR-3, MCF-7, T47D, ZR-75-1 cells and mice Breast Cell Epithelial Cell Line NMuMG Tested Concentrations: 3 μM Incubation Duration: 3 days/7 days Experimental Results: Displayed anti-proliferative activity against both mouse and human breast cancer cells. Growth of mouse fibrosarcoma cell lines derived from ras transgenic mice was not affected. In vitro cellular experiments for IN1341 involve treating cells with the compound and measuring its effects on cell proliferation, mitochondrial function, and cell death. The inhibition of proliferation is assessed by counting cells or measuring metabolic activity. Mitochondrial membrane potential is measured using dyes such as JC-1 or TMRE. The induction of apoptosis is assessed by measuring caspase activation or annexin V staining. |
| Animal Protocol |
In vivo animal experiments for IN1341 are not extensively detailed in the available literature. As a mitochondrial toxin and proliferation inhibitor, it could be evaluated in mouse models of breast cancer to assess its anti-tumor efficacy. Its effects on tumor growth and metastasis would be assessed.
|
| ADME/Pharmacokinetics |
IN1341 has a molecular weight of 362.21 and a molecular formula of C16H15IN2. It is also known as F16. The compound has a CAS number of 36098-33-6. It is a fluorescent, delocalized lipophilic cation that selectively inhibits proliferation of mammary epithelial and breast cancer cells.
|
| Toxicity/Toxicokinetics |
IN1341 is a research compound that is not intended for human use. Its toxicological profile is not extensively characterized in the available literature. As a mitochondrial toxin, it may have potential off-target effects on normal cells. As with all research chemicals, standard safety precautions should be followed when handling.
|
| References |
[1]. Fantin VR et al. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell. 2002 Jul;2(1):29-42.
[2]. Fantin VR et al. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer Res. 2004 Jan 1;64(1):329-36. |
| Additional Infomation |
IN1341 (F16) is a fluorescent, delocalized lipophilic cation that selectively inhibits proliferation of mammary epithelial cells, neu-overexpressing cells, and various breast cancer cell lines. It acts as a mitochondrial toxin by preferentially binding to and disrupting mitochondrial membrane function. It has a molecular weight of 362.21 and a molecular formula of C16H15IN2.
|
| Molecular Formula |
C16H15IN2
|
|---|---|
| Molecular Weight |
362.21
|
| Exact Mass |
362.027
|
| CAS # |
36098-33-6
|
| PubChem CID |
11325914
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
0.166
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
292
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[N+]1=CC=C(/C=C/C2=CNC3=C2C=CC=C3)C=C1.[I-]
|
| InChi Key |
UURAKYSOOXPORG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2.HI/c1-18-10-8-13(9-11-18)6-7-14-12-17-16-5-3-2-4-15(14)16;/h2-12H,1H3;1H
|
| Chemical Name |
3-[(E)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]-1H-indole;iodide
|
| Synonyms |
IN 1341; IN-1341; IN1341
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 31 mg/mL (~85.59 mM)
Ethanol : ~1 mg/mL (~2.76 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7608 mL | 13.8041 mL | 27.6083 mL | |
| 5 mM | 0.5522 mL | 2.7608 mL | 5.5217 mL | |
| 10 mM | 0.2761 mL | 1.3804 mL | 2.7608 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
